Trimetazidine and cardioprotection: Facts and perspectives

Angiology

Volumn 66, Issue 3, 2015, Pages 204-210

  Tsioufis, Konstantinos ^a   Andrikopoulos, George ^b   Manolis, Athanasios ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Coronary heart disease; Heart failures; Stable angina; Trimetazidine

Indexed keywords

ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; IVABRADINE; METOPROLOL; NICORANDIL; NITRIC ACID DERIVATIVE; RANOLAZINE; TRIMETAZIDINE; CARDIOTONIC AGENT; VASODILATOR AGENT;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR MORTALITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENERGY YIELD; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART FAILURE; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); POST HOC ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STABLE ANGINA PECTORIS; ANGINA, STABLE; CHRONIC DISEASE; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; TREATMENT OUTCOME;

ANGINA, STABLE; CARDIOTONIC AGENTS; CHRONIC DISEASE; HEART FAILURE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84925581433     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714530040     Document Type: Article

References (67)

1. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013;34(38): 2949-3003.
2. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003;14(2):171-179.
3. Brodbin P, O'Connor CA. Trimetazidine in the treatment of angina pectoris. Br J Clin Pract. 1968;22(9):395-396.
4. Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution). http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Trimetazidine-31/WC500129195.pdf. March 9, 2012.
5. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990; 4(4):853-859.
6. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267-2274.
7. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003;2:16.
8. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27(8):942-948.
9. Levy S, the Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol. 1995;76(6):12B-16B.
10. Thrainsdottir I, von Bibra H, Malmberg K, Ryden L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol. 2004;44(1): 101-108.
11. Michaelidis PA, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest. 1997;13(1):8-14.
12. Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011; 120(2):59-72.
13. Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163(3):320-325.
14. Dyck JR, Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol. 2002;34(9): 1099-1109.
15. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000; 86(5):580-588.
16. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26(8):949-958.
17. Stanley WC, Marzilli M. "Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine". Fundam Clin Pharmacol. 2003;17(2):133-145.
18. Fragasso G, Piatti PM, Monti L, et al. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146(5):E18.
19. Di Napoli P. Anti-ischemic cardioprotection with trimetazidine. Heart Metab. 2008;41:25-29.
20. National Institute for Health and Clinical Excellence. NICE Clinical Guideline. Management of Stable Angina. London: National Institute for Health and Clinical Excellence, 2011. http://www.nice.org.uk/guidance/CG126 [Accessed July 17, 2013].
21. Passeron J.Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study. Presse Med. 1986;15(35):1775-1778.
22. Sellier P, Audouin P, Payen B, Corona P, Duong TC, Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol.1987;33(2):205-207.
23. Prasad R, Singh HK. The efficacy of trimetazidine in stable effort angina. A double blind placebo controlled study. Ind Med J. 1989; 83(3):54-58.
24. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol. 1998;82(7):898-901.
25. Koylan N, Bilge AK, Adalet K, Mercanoglu F, Büyüköztürk K, TTS Group. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol. 2004; 59(6):644-650.
26. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994;37(3):279-288.
27. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin. 2004;20(9): 1447-1454.
28. Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs. 2003;3(5):361-369.
29. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart. 1997; 78(4):353-357.
30. Manchanda SC. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. Int J Cardiol. 2003;88(1):83-89.
31. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in angina combination therapy-the TACT study: Trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12(1):35-42.
32. Szwed H, Sadowski Z, Pachocki R, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther. 1999; 13(3):217-222.
33. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev. 2005;(4):CD003614.
34. Vitale C, Spoletini I, Malorni W, Perrone-Filardi PP, Volterrani M, Rosano GMC. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina-The VASCO-angina study. Int J Cardiol. 2013;168(2):1078-1081.
35. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J. 1992;13(8):1109-1115.
36. Polonski L, Dec I, Wojnar R, Wilczek K. Trimetazidine limits the effects of myocardial ischemia during percutaneous coronary angioplasty. Curr Med Res Opin. 2002;18(7):389-396.
37. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart. 2007;93(6):698-702.
38. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007;93(6): 703-707.
39. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2007;7(2): 143-150.
40. Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino). 1992;33(4):486-491.
41. Tunerir B, Colak O, Alataş O, Beşoʇul Y, Kural T, Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg. 1999;68(6):2173-2176.
42. Iskesen I, Kurdal AD, Eserdag M, Cerrahoglu M, Sirin BH. Trimetazidine may protect the myocardium during cardiac surgery. Heart Surg Forum. 2009;12(3):E175-E179.
43. Demirelli S, Karakelleoʇlu S, Gündoʇdu F, et al. The Impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J. 2013;43(7):462-467.
44. Dehina L, Vaillant F, Tabib A, et al. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia. Naunyn Schmiedebergs. Arch Pharmacol. 2013;386(3):205-215.
45. Xu X, Zhang W, Zhou Y, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. Clin Drug Investig. 2014;34(4):251-258.
46. International clinical trials registry platform. The efficAcy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous coronary intervention. ATPCI study An international, multicentre, randomised, double-blind, placebocontrolled study in patients treated for 2 to 4 years. ATPCI. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudr act-number:2010-022134-89 [Accessed March 6, 2014].
47. Herrmann G, Decherd GM. The chemical nature of heart failure. Ann Intern Med. 1939;12(8):1233-1244.
48. CIBIS Investigators and Committees. A randomized trial of b-blockade in heart failure: the Cardiac Bisoprolol Insufficiency Study (CIBIS). Circulation. 1994;90(4):1765-1773.
49. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349-1355.
50. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-1435.
51. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and ventricular enlargement trial. N Engl J Med. 1992;327(10):669-677.
52. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
53. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386): 759-766.
54. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J. 1990;11(3):207-212.
55. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118(12):1250-1258.
56. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001;22(23):2164-2170.
57. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effects on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91(2):161-165.
58. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25(20):1814-1821.
59. Gunez Y, Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels. 2009;24(4): 277-282.
60. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a metaanalysis of randomized controlled trials in heart failure. Heart. 2011;97(4):278-286.
61. Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol. 2011;34(6):395-400.
62. Kim JS, Kim CH, Jeong MH. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean acute myocardial infarction registry. Clin ResCardiol. 2013;102(12):915-922.
63. Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsoti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d' abruzzo trimetazidine trial. J Cardiovasc Pharmacol. 2007;50(5):585-589.
64. Liu F, Yin L, Zhang L, et al. Trimetazidine improves right ventricular function by increasing miR-21 expression. Int J Mol Med. 2012;30(4):849-855.
65. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y,. Ge J. Additional use of trimetazidine in patients with chronic heart failure a meta-analysis. JACC. 2012;59(10):913-922.
66. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5(4):271-278.
67. Iyengar SS, Rosano GM. Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). Am J Cardiovasc Drugs. 2009;9(5):293-297.